Medical Network August 6th, a few days ago, the 2018 (35th) National Pharmaceutical Industry Information Annual Conference grandly announced the "2018 China's pharmaceutical research and development product line of the best industrial enterprises" list, well-known, research and development investment Pharmaceutical companies such as Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu Haosen Pharmaceutical Group Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Zhejiang Haizheng Pharmaceutical Co., Ltd., Shanghai Pharmaceutical Group Co., Ltd., etc. are on the list. There are also some unexpected companies such as Sichuan Baili Pharmaceutical Co., Ltd., Jiangsu Osei Kang Pharmaceutical Co., Ltd., Puluo Pharmaceutical Co., Ltd., Yuekang Pharmaceutical Group Co., Ltd., etc. (complete list to the end of the article) .
â–Representative enterprise R&D investment and research and development results
The amount of R&D investment by enterprises is the basic guarantee for enterprises to maintain strong R&D momentum, which is mainly reflected in the number of R&D personnel, R&D investment costs and R&D investment intensity (R&D investment funds account for the proportion of current sales revenue).
20 of the companies on the list have more than 10 listed companies (Elohim Pharmaceutical privatization of delisting from the Hong Kong GEM in mid-2017), most of these companies R & D investment intensity is far more than China's pharmaceutical industry average at 1.7 The level around %.
In which the number of R & D staff of more than 2,000 people have Hengrui Medicine, CTTQ (Chinese bio-pharmaceutical), Cologne medicine three companies; R & D investment is only Hengrui Medicine and CTTQ two companies worth more than $ 1 billion, more than 1.5 billion yuan, R & D investment intensity of more than 10%.
The basic R&D investment is as follows:
Note: The data information is sorted according to the annual report of the listed company, and it is inevitable to omit it for reference.
â–20 strong enterprises in the field of research product treatment
The 20 pharmaceutical companies listed on the list have had more than 1,300 applications for research and implementation in 2016, including the number of companies, the number of varieties, and the number of companies involved in the treatment of anti- tumor and immunomodulators, digestive and metabolic drugs, and cardiovascular drugs. The number is the highest.
Among the more than 1300 acceptance numbers, only 27 are in the R&D acceptance number of Chinese patent medicines, and the basic situation of the research and development product lines of the top 20 research and development is as follows:
Note: According to the CDE review data, manual finishing, it is inevitable to overlook, for reference.
â–20 companies in the first class of new drugs in research product line
The first class of new drugs is a direct manifestation of the company's R&D and innovation capabilities. There are 13 of the top 20 pharmaceutical companies in the list, and there are more than 140 new drugs in the research, involving more than 140 products (about 70 common names). Among them, 16 products are in the application production stage (the general name is about 8), among which the anti-tumor and immunomodulatory agent of erlotinib hydrochloride and capsules of Zhengda Tianqing have obtained production approval on May 8 this year.
The status of the review of the first class of new drugs in these 13 pharmaceutical companies, the distribution of the treatment areas and the basic conditions of the varieties are as follows:
Note: According to the CDE review data, manual finishing, it is inevitable to overlook, for reference.
Attachment: List of the top 20 best industrial enterprises in China's pharmaceutical R&D product line in the 2018 China Pharmaceutical Information and Information Center:
Soybean phospholipid oil
Jiangsu Chenwei Biology and Technology Co. LTD , https://www.cwsoybean.com